MDT | Resuscitation of Patient with High Risk of Acute Myeloid Leukemia and Severe Coronary Stenosis
2022-05-25
In September 2021, Mr. Yang was diagnosed with acute myeloid leukemia and severe stenosis of the left main coronary artery, and came to Peking University People's Hospital for treatment. Acute myeloid leukemia has the highest malignancy degree and the shortest survival time among all hematological tumors. Severe stenosis of the left main coronary artery caused large area of myocardial ischemia risk. Sudden death might happen at any time. Each disease is dangerous and could be fatal.
The multidisciplinary diagnosis and treatment (MDT) team composed of Peking University Institute of Hematology, the Department of Cardiology and the Department of Cardiac Surgery of Peking University People's Hospital joined hands and cooperated closely to launch the MDT process，worked together to evaluate the diagnosis and treatment of Yangs condition, and jointly formulated a scientific, accurate and efficient treatment plan.
Yang first received combined targeted therapy for leukemia, with dependable blood support from the Department of Transfusion Medicine of the MDT team. Targeted therapy lasted for 3 weeks, and Yang has experienced four weeks serious pancytopenia period. Under the escort of the MDT team, Yang survived the targeted therapy period safely.
Fortunately, Yang's hemogram stabilized and the Department of Cardiac Surgery performed coronary artery bypass grafting in time. With the strong support of the Department of Hematology of the hospital, the Department of Cardiac Surgery gave full play to its own disciplinary advantages and applied minimally invasive, off-pump and arterial bridge technologies to the patient, which greatly reduced surgical trauma and avoided additional risks brought by blood system problems.
Allogenic hematopoietic stem cell transplantation is the main and even the only method to cure hematologic malignancy. After two courses of targeted drugs therapy, and three months after bypass surgery, the hematopoietic stem cell transplantation team of Peking University Institute of Hematology applied the famous "Beijing Protocol" to Yang to perform the semi-compatible sibling hematopoietic stem cell transplantation. The transplantation process was basically smooth. His daughters hematopoietic stem cells were successfully transplantedhis body and Yang was discharged from hospital 5 weeks after transplantation.
"Looking back on my treatment experience in Peking University People's Hospital, I deeply felt the exquisite medical skills and noble medical ethics. Only through experience can we understand." Yang wrote in his letter of thanks.
